

Current Contraceptive Options and Approaches

Nisha McKenzie, PA-C CEO and Founder - Women's⁺ Health Collective AASECT Certified Sexuality Counselor Menopause Society Certified Provider ISSWSH Fellow



COMMON POTENTIAL CI'S

- Pregnancy
- Smoking status (namely if >=35 y/o)
- Cardiovascular conditions
 - HTN (even well controlled with meds)
 - VTA/clotting disorders
- Migraine with aura
- h/o hormone receptor positive cancer
- Postpartum/breastfeeding



CONSIDERATIONS

- Not all people capable of pregnancy identify as women
 - Important to consider counseling needs of trans, NB, and gender diverse folx
- Discussions should not focus solely on preventing unintended pregnancy
- Shared decision making
 - Acknowledge patient as expert on their body and preferences
 - HCP contributes medical knowledge/options and helps relate to pt preferences
 - Research has found that patients are more satisfied with medical experience and their method when shared decision-making is utilized
- "Do you happen to... (know if you'd like to try to conceive in the future, have a general timeline for when you might want to try to conceive, etc)". Or - "are you planning future pregnancies, unsure or no?"
- "Do you have some ideas about what is important to you about your method of birth control?"

CHOOSING A COC

- Cost/accessibility
- Monophasic vs multiphasic
- Cyclic vs continuous dosing
 - Pt preference
 - Endometriosis/adenomyosis
- Ethinyl estradiol dose
 - <= 35 mcg for contraception (may use up to 50mcg for AUB)
- Progestin type
 - User's choice
 - Slightly increased risk VTE with newer progestins (desogestrel, drospirenone)
- 21/7 vs 24/4




COC MOA

- *Estrogen suppresses FSH to prevent folliculogenesis
- Inhibition of GnRH from hypothalamus
- Inhibition of LH and FSH
- Disruption of midcycle LH surge
- All leading to suppression of ovulation
- Estrogen helps control bleeding patterns by providing endometrial stability sufficient to produce regular withdrawal bleeding
- Progestins thin the endometrium, making it less suitable to implantation
 - They also thicken cervical mucus
 - They also impair tubal motility and peristalsis



45% OF PREGNANCIES ARE UNINTENDED



Guttmacher Institute

UNINTENDED PREGNANCY FACTS

- 10-15% of all sexually active women use no birth control method
- 2.8 million unintended pregnancies in 2011
 - 42% ended in abortion
- Unintended pregnancies disproportionately affect low income and minority communities (up to 112/1000 women)

Finer and Zolna NEJM 2016, Guttmacher Institute 2019



UNINTENDED PREGNANCY FACTS

- The unintended pregnancy rate is significantly higher in the US than in many other developed countries
- The unplanned pregnancy rate in 2011 was 22/1,000 women aged 15-44
- The abortion rate in 2011 was 17/1,000 women aged 15-44 (Jones RK and Jerman J, Abortion incidence and service availability in the US, 2011, Perpectives on Sexual and Reproductive Health, 2014, 46(1):3-14, doi:10.1363/46e0414.)



UNINTENDED PREGNANCY RATES

Unintended pregnancy is increasingly concentrated among low-income women.

Rate (no. per 1,000 women aged 15-44)





CONTRACEPTIVE FACTS

- Between 2002 and 2012 we saw an increase in LARC use from 2 -12% (Guttmacher Institute)
- 83% of black women at risk of unintended pregnancy are currently using a contraceptive method, compared with 91% of their Hispanic and white peers, and 90% of their Asian peers (Jones J, Mosher W, Daniels K, Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995, National Health Statistics Reports, 2012, No.)
- In the US, average desired family size is 2 children. To achieve this, a woman must use contraceptives for roughly 3 decades (Sonfield A, Hasstedt K and Gold RB, Moving Forward: Family Planning in the Era of Health Reform: Guttmacher Institute, 2014)
- Couples who do not use any method of contraception have ~ 85% chance of experiencing a pregnancy over the course of a year (Sonfield A, Hasstedt K and Gold RB, *Moving Forward: Family Planning in the Era of Health Reform*: Guttmacher Institute, 2014)



CONTRACEPTIVE FACTS

- IUD is 45 times as effective as oral contraceptives in preventing pregnancy
- IUD is 90 times as effective as male condoms at preventing pregnancy

Brief of the Guttmacher Institute and Professor Sara Rosenbaum as *Amici Curiae* in Support of the Government, Kathleen Sebelius v. Hobby Lobby Stores, Inc and Conestoga Wood Specialties Corporation v. Kathleen Sebelius, Nos. 13-354 & 13-356, <<u>http://www.guttmacher.org/media/guttmacher_scotus_amicus_brief.pdf</u>>, accessed Aug. 18, 2014.



CONTRACEPTIVE METHOD CHOICE

Most effective method used in the past month by U.S. women, 2018

Total	72,663,695	100.0	100.0	100.0
No method	25,219,648	34.7	11.0	na
Other method [†]	121,186	0.2	0.2	0.3
Emergency contraception	95,021	0.1	0.2	0.2
Patch	225,504	0.3	0.4	0.5
Vaginal ring	594,391	0.8	1.2	1.3
Natural family planning	1,241,390	1.7	2.6	2.6
Injectable	1,422,760	2.0	2.1	3.0
Implant	1,459,234	2.0	2.6	3.1
Withdrawal	2,666,523	3.7	5.8	5.6
Partner vasectomy	4,101,347	5.6	8.5	8.6
IUD	6,101,248	8.4	12.0	12.9
Male condom	6,125,842	8.4	13.2	12.9
Pill	10,139,377	14.0	16.4	21.4
Permanent female method [*]	13,150,225	18.1	23.9	27.7
METHOD	No. of women	% of women aged 15-49	% of sexually active women not seeking pregnancy aged 15–49 (N=46,355,763)	% of contraceptive users aged 15–49 (N=47,444,047)

*Tubal ligation and tubal implants. [†]Diaphragm, internal (female) condom, foam, cervical cap, sponge, suppository, jelly, cream and other methods. *Notes:* "Sexually active women not seeking pregnancy" includes all women who report sexual activity in the previous three months; are not currently pregnant, seeking to become pregnant or postpartum; and are not noncontraceptively sterile. "Contraceptive users" includes all women who use a method, regardless of sexual activity. Percentages may not add to 100.0 because of rounding. na=not applicable. *Source:* reference 4.




guttmacher.org

ABORTION FACTS

- Some 55% of people who obtained an abortion had previously had at least one birth (Jones RK, Medicaid's role in alleviating some of the financial burden of abortion: findings from the 2021–2022 Abortion Patient Survey, Perspectives on Sexual and Reproductive Health, 2024, <u>https://doi.org/10.1111/psrh.12250</u>.)
- The abortion rate in 2017 was 13.5 abortions per 1,000 women aged 15-44, down 8% from 14.6 per 1,000 in 2014. This is the lowest rate ever observed in the US. In 1973 when abortion became legal, the rate was 16.3/1,000.
- Approximately one in four women are expected to have an abortion by age 45, given 2020 abortion rates.
- In 2014, 51% of abortion patients were using a contraceptive method at the time they became pregnant, most commonly condoms (24%) or a short acting hormonal method (13%) (Jones RK, Reported contraceptive use in the month of becoming pregnant among US abortion patients in 2000 and 2014, *Contraception*, 2018)

Medication abortions accounted for almost two-thirds of all clinician-provided abortions in the United States in 2023.




Sources: Guttmacher Abortion Provider Census and Monthly Abortion Provision Study.

guttmacher.org



In 2021, 81% of abortions in the formal US health care system occurred at nine weeks of pregnancy or earlier, and 94% occurred in the first 13 weeks.



Source: Centers for Disease Control and Prevention, 2023.



guttmacher.org

ABORTION FACTS: GUTTMACHER.ORG

 27,000 more medication abortions were mailed in the 6 months after the Dobbs decision than the expected number had the ruling not been issued


Per examination of ab pill distribution by online vendors, telehealth orgs, and community networks

- The proportion of pts traveling to other states to obtain ab care has doubled (~1/5 in the 1st 6 mo of 2023, vs 1/10 in 2020)
- The number of abs in the US has increased
 - 11% increase in clinician-provided abs 2020-2023
- Prelim estimates on the risk of maternal mortality in the case of a national ab ban:
 - Maternal mortality would increase by 24%
 - Non-Hispanic Black birthing parents would see a 39% increase in maternal deaths



TRENDS IN ABORTION

The U.S. abortion rate reached a historic low in 2017.





www.guttmacher.org

WHO IS A CANDIDATE FOR A LARC?





IUD PROS AND CONS

YAY

- Highly effective and easily reversible
- Very few CIs to placement (think uterine anomaly)
- Appropriate for nulliparous women, adolescents, and peri/postmeno
- Higher rates of satisfaction and compliance vs short acting contraceptives
- Low expulsion rates
 - LNG IUD 3.3%
 - Cu IUD 9.2%
- No increased risk of PID
- Local effect, not systemic (will not decrease systemic T)

NAY

- Requires office visit to insert and remove
- Pain with insertion
- Limited data re: sexual side effects
 - CHOICE Project: no difference in desire
- LNG is androgenic, targets the AR
- Several reports/studies showing increased vaginal complaints/vaginitis with IUDs
- CU IUD shows increased in uterine bleeding and dysmenorrhea



IMPLANT PROS AND CONS

YAY

- Prospective studies x 2 show improvement in FSFI/sexual function
- Low doses of circulating progestin suppresses ovulation
- Ease of placement (think pts with vaginismus or h/o abuse)

NAY

- Does not have a significant impact on suppression of systemic estradiol
 - Explaining AUB (11%)
- Mood swings (2.3%)
- Weight gain (2.3%) (2.8lbs after 1yr, 3.7lbs after 2 yrs)
- Acne (1.3%)
- Requires training by Organon prior to ordering



Product	Device	FDA Approved Duration	FDA Approved Indication	Mechanism of Action
Etonogestrel Subdermal Implant • Nexplanon 68mg		• 3 yrs	Contraception	Suppresses ovulation, increases viscosity of cervical mucous, alters endometrial lining
 Levonorgestrel IUD Skyla 13.5mg (28x30mm) Kyleena 19.5mg Liletta 52mg (32x32mm) Mirena 52mg 		 3 years 5 years 8 years 8 years 	 Contraception Contraception Contraception/ Menorrhagia (5 years) 	Thickens cervical mucous, alters endometrial lining impairing implantation, may inhibit binding of sperm and egg
Copper IUD Paragard 		• 10 years	Contraception (off label emergency contraception)	Copper ions toxic to sperm

LARC CONTINUATION RATES FROM THE CHOICE PROJECT

Method	1 Year	2 Year	3 Year
LNG IUD	87.3	76.7	69.8
Copper IUD	84.3	76.2	69.7
Implant	81.7	68.7	56.2
LARC methods overall	85.8	75.2	67.2
Non-LARC methods overall	55.8	39.5	31.0



NON CONTRACEPTIVE COC HEALTH BENEFITS

Maguire K, et al AJOG 2011

- Menorrhagia/Heavy menstrual bleeding/Anemia
 - 40% decrease in blood loss after 3 months of use
- Dysmenorrhea
 - 66% decreased cramping
 - Low-dose pills improve menstrual pain over time
- Regulates bleeding pattern
- Ovarian cysts
- Cancer prevention
 - Ovarian, endometrial, colon




NON CONTRACEPTIVE COC HEALTH BENEFITS

Maguire K, et al AJOG 2011

- Bone
 - Women in their 40s show a 25% decrease in hip fractures later in life
 - Dose related effect on BMD
- Fibroids
 - Pain management and control of AUB related to leiomyoma
- PMDD
 - Most data on drospirenone containing OCPs
- Acne
 - Increased SHBG resulting in decreased free testosterone
 - 50% decrease in inflammatory lesions





MENSTRUAL CYCLE



The Takeaway: Know your OCP type

Almost all OCPs comprised of ethinyl estradiol

International Society for the Stur of Women's Sexual Health

- Stronger effect on hepatic (inc SHBG, HDL VLDL, Angiotensinogen)
- more potent than estradiol, longer half life
- 10, 20, 30, 35 mcg

Estrogen	FSH	HDL-C	SHBG	CBG	Angio
E ₂	100	100	100	100	100
Estriol	30	20			
Estrone sulfate	90	50	90	70	150
CEE	110	150	300	150	500
Equilin sulfate		600	750	600	750
EE	12,000	40,000	50,000	60,000	35,000

Legend: Angio = angiotensinogen; CBG = cortisol-binding globulin;

CEE = conjugugated estrogens; EE = ethinyl estradiol; HDL-C = high density lipoprotein-cholesterol;

HF = hot flushes; SHBG = sex hormone-binding globulin.

WWW.ISSWSH.ORG



SHARED DECISION MAKING

- Individualize
 - Sexual history
 - Co-morbidities
 - Complex psychosocial and contextual factors
 - Stress, relationships, culture, interpersonal, body image, schedule, etc
 - Reproductive health goals
 - h/o tampon use?
 - Comfort with route of administration
 - Logistical and cost barriers
- ACOG has good video resources for shared decision making
- Address any misconceptions



MAIVE, 16 YEARS OLD



- Menarche at 12 years old
- Heavy menstrual bleeding and dysmenorrhea
- Frequency q 27-30 days, Duration 5-7 days
- Accompanied by her mom to today's visit
- Misses 2-3 days of school per month due to HMB and dysmenorrhea
- Denies being sexually active
- Hgb/Hct 12/36 (nml adolescent range 12-15/37-43)



PEDIATRIC LARC RECOMMENDATIONS

ACOG

 "LARCs have higher efficacy, higher continuation rates, and higher satisfaction rates compared with short-acting contraceptives among adolescents who choose to use them. Complications of intrauterine devices and contraceptive implants are rare and differ little between adolescents and women, which makes these methods safe for adolescents"

AAP

 "Pediatricians should counsel about and ensure access to a broad range of contraceptive services for their adolescent patients. This includes educating patients about all contraceptive methods that are safe and appropriate for them and describing the most effective methods first."

CAN MINORS IN YOUR AREA CONSENT TO CONTRACEPTION? MOST STATES ALLOW MINORS TO CONSENT WITHOUT PARENTAL INVOLVEMENT

- 27 states and the District of Columbia explicitly allow all individuals to consent to contraceptive services or those at a specified age (such as 12 or 14) and older to consent to such care.
- 19 states allow only certain categories of people younger than 18 to consent to contraceptive services
- 4 states have no explicit policy or relevant case law

*https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law



CURRENT POLICY IN YOUR STATE

In MI, people younger than age 18 may consent to:

Contraceptive Services	STI Services	Prenatal Care	Adoption	Medical Care for Minor's Child	Abortion Services
Some	All	All	Parental consent	All	Parental consent

https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law






MAIVE

- Full discussion of risks, benefits and efficacy of each method as well as contraindications
- Maive and her mom participated in shared decision making and decided to proceed with oral contraceptives
- It is important to have discussion re: dosing/timing, expectations, potential side effects and what to do if she misses a pill
- Always use these opportunities to discuss safer sex and STI screening
- Follow up is scheduled for 3 months





Effectiveness of Family Planning Methods

CS 242797

CONDOMS SHOULD ALWAYS BE USED TO REDUCE THE RISK OF SEXUALLY TRANSMITTED INFECTIONS.

Other Methods of Contraception

Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.

Emergency Contraception: Emergency contraceptive pills or a copper IUD after unprotected intercourse substantially reduces risk of pregnancy.

Adapted from World Health Organization (WHO) Department of Reproductive Health and Research, Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP). Knowledge for health project. Family planning: a global handbook for providers (2011 update). Baltimore, MD; Geneva, Switzerland: CCP and WHO; 2011; and Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.



U.S. Department of Health and Human Services Centers for Disease Control and Prevention



MAIVE FOLLOW UP

3 months

- B/P WNL
- Forgetting to take pill at same time every day leading to breakthrough bleeding
- Is now sexually active
 - Counsel regarding STIs
- Discuss apps or reminders in phone to take pill at the same time
- Also discuss other methods of contraception and bleeding control
- She decided she would like to try a new app and work on taking it at the same time daily over the next few months



MAIVE FOLLOW UP



6 months

- B/P WNL
- No longer having BTB, but still forgetting her pill often
- Using condoms most of the time
 - Counsel regarding STIs
- Discuss decreased efficacy with irregular use of the pill
- Since she was forgetting so often, she stopped taking the pill completely about a month ago




POINTS TO CONSIDER

- Comfort with pelvic exam
 - Can patient use a tampon?
- Common side effects with each LARC
- History of keloid formation?
- Contraindications:
 - Pregnancy
 - Known or suspected breast cancer
 - Abnormal uterine morphology (IUD)
 - Acute pelvic inflammatory disease (IUD)
 - Hypersensitivity





Amenorrhea Rates at the End of 1st Year





WOMEN'S⁺ HEALTH COLLECTIVE

- Maive's LMP was about 2 weeks ago
- She has not had unprotected sex since her LMP
- Does she need back up contraception after implant?



Quick Start Algorithm for Hormonal Contraception²





REPRODUCTIVE HEALTH ACCESS PROJECT – QUICK START ALGORITHM

1 If pregnancy test is positive, provide options counseling.

2 CDC advises that benefits of starting contraceptive likely exceed risk of early pregnancy.

3 For patients with body mass index over 25, levonorgestrel EC works no better than placebo. Ulipristal EC has higher efficacy than levonorgestrel EC for those who had unprotected sex 3-5 days ago. Because hormones may decrease the efficacy of ulipristal, the new method should be started no sooner than 5 days after ulipristal. Consider starting injection/IUD/implant sooner if benefit outweighs risk.



COMPARING LARCS

LARC	Size	FDA Approved length of use	FDA Approved for HMB
Nexplanon (68 mg subdermal etonogestrel implant)	4 cm long, 2 mm diameter	3 years	
Paragard (Cu-IUD)	32 mm x 36 mm	10 years	
Mirena (*LNG-IUD, 52 mg)	32 mm x 32 mm	8 years	\checkmark
Liletta (LNG-IUD, 52 mg)	32 mm x 32 mm	8 years	
Kyleena (LNG-IUD, 19.5 mg)	28 mm x 30 mm	5 years	
Skyla (LNG-IUD, 13.5 mg)	28 mm x 30 mm	3 years	






IMPLANTING ETONOGESTREL IMPLANT

1: Lying on back with non-dominant arm flexed at elbow and externally rotated so hand is under head

2: ID insertion site 8-10 cm proximal to medial epicondyle and 3-5 cm posterior to (below) sulcus between biceps and triceps (so overlying triceps)

3: Use surgical marker to mark insertion site and a spot 5cm proximal for guide

Guiding Mark




IMPLANTING ETONOGESTREL IMPLANT

4: Clean with antiseptic solution from insertion site to guide mark

5: Anesthetize insertion area

6: Remove protection cap and view white implant inside tip of needle

7: Puncture skin with tip of needle slightly angled < 30 degrees






IMPLANTING ETONOGESTREL IMPLANT

8: Insert until bevel is just beneath skin, then lower applicator to horizontal position and lift

9: Unlock the purple slider by pushing it slightly down and pulling it fully back

10: Apply butterfly bandaid or steri-strip

11: apply pressure bandage to be left in place clean and dry for 24 hours







MAIVE FOLLOW UP

1 year

- Very happy with her choice of the implant
- Over the past 6 months she has been diagnosed with Bipolar II Disorder
- She was started on Lamotrigine
- Can she continue this method of contraception?
- Are there any new recommendations based on the addition of this new medication?



MEDICAL ELIGIBILITY CRITERIA FOR INITIATING CONTRACEPTION

Condition	Sub-Condition	Cu-IUD	LNG-IUD	Implant	DMPA	POP	СНС
Anticonvulsant therapy	a) Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)	1	1	2*	1*	3*	3*
	b) Lamotrigine	1	1	1	1	1	3*

Key:				
1 No restriction (method can be used)	3 Theoretical or proven risks usually outweigh the advantages			
2 Advantages generally outweigh theoretical or proven risks	4 Unacceptable health risk (method not to be used)			



https://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf

MEC APP

US MEC US SPR



ZURI

Patient History	 42 and recently single Previous husband had a vasectomy Cycles becoming variable – frequency ranging every 3-6 weeks She considers her flow to be normal HTN controlled (124/78) 12 pack year history – quit smoking 10 years ago Migraines with aura G2P2 BMI 31kg/m²
Current medications	 Lisinopril 10mg qd M=Ca 600mg with Vitamin Dr 1000 IUs
Contraceptive history	 Infertility – conceived twice with IUI Used OCPs x 5 yrs prior to trying to conceive





ZURI

Shared decision making

- Decrease risk of unintended pregnancy
- Not interested in a permanent option
- Discuss hormonal impact on blood pressure
- Variable cycle length
- Discuss risks of hormone use with migraines
- STI counseling/testing
- Previous infertility dispel myths
- Zuri is very interested in a LARC
 - Discuss differences, common side effects (copper vs LNG), and implant
 - Remind increased risk of IUD displacement with use of menstrual cup






MEDICAL ELIGIBILITY CRITERIA

Condition	Sub-Condition	Cu-IUD	LNG-IUD	Implant	DMPA	POP	СНС
		I C	I C	I C	I C	I C	
Hypertension a) Adequately controlled hypertension b) Elevated Decomposition (properly taken measurements) i) Systolic 140-159 or diastolic 90-99 ii) Systolic ≥160 or diastolic ≥100 [‡]		1*	1*	1*	2*	1*	3*
		1*	1*	1*	2*	1*	3*
		1*	2*	2*	3*	2*	4*
	c) Vascular disease	1*	2*	2*	3*	2*	4*
Headaches	a) Nonmigraine (mild or severe)	1	1	1	1	1	1*
	b) Migraine						
	i) Without aura (includes menstrual migraine)	1	1	1	1	1	2*
	(1) With aura	1	1	1	1	1 (4*




IUD INSERTION TECHNIQUE



- Insert appropriately sized speculum (gracious use of lube)
- Apply antiseptic to cervix
- Tenaculum gently placed at anterior or posterior lip of cervix
- Gentle traction to align uterine cavity
- Sound to note uterine depth with metal or plastic sound
- Maintain sterility of portion to enter uterine cavity (use packaging to move flange)



IUD INSERTION TECHNIQUE



- Insert IUD to either:
 - 2cm prior to depth set on flange
 - To fundus, then withdraw 2cm
- Pull back slider to marks on the insertion device deploying arms into cavity
- Advance device to fundus as noted on flange
- Then pull slider entirely back to the bottom of the window
- Slowly remove insertion device
- Cut strings to 3-4 cm



CHALLENGING IUD INSERTION TIPS

- Consider repositioning farther down on table, larger speculum, moving light
- Use tenaculum may also reposition based on angle of uterus
- Use dilators
- Consider misoprostol, NSAIDs, anxiolytics, nitrous oxide
- Consider referral and insertion under sedation/imaging
- Consider ultrasound, MRI, CT after difficult insertion if concerns for perforation



ZURI RECOMMENDATIONS AND MONITORING

- Zuri proceeded with LNG 52mg IUD insertion
- Recommend follow up within 1-3 months
 - Assess response/satisfaction
 - Check strings
 - Assess B/P, migraines
 - Address sexuality/STI testing again
- Check strings at home after each bleed or prn
- Annual strings checks in the clinic





ZURI FOLLOW UP

- Zuri returns 6 years after insertion (now 48 yrs old)
- No concerns with IUD has been happy with her response rare and light bleeding only
- New male partner he has also had a vasectomy
- Migraines and B/P still well controlled
- Is she a candidate for another LNG IUD?







